摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(3-甲基-1-丁烯-2-基)吗啉 | 7694-49-7

中文名称
4-(3-甲基-1-丁烯-2-基)吗啉
中文别名
——
英文名称
N-(3-Methyl-1-buten-2-yl)morpholine
英文别名
2-(4-morpholinyl)-3-methylbutene;4-(1-isopropylvinyl)morpholine;4-(1-isopropyl-vinyl)-morpholine;4-<3-Methyl-1-buten-2-yl>-morpholin;2-Morpholino-3-methyl-buten-(1);2-Morpholino-3-methyl-1-buten;Morpholine, 4-(2-methyl-1-methylenepropyl)-;4-(3-methylbut-1-en-2-yl)morpholine
4-(3-甲基-1-丁烯-2-基)吗啉化学式
CAS
7694-49-7
化学式
C9H17NO
mdl
——
分子量
155.24
InChiKey
QXUDOKMXAMFEDP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    228.8±29.0 °C(Predicted)
  • 密度:
    0.926±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    11
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.78
  • 拓扑面积:
    12.5
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-(3-甲基-1-丁烯-2-基)吗啉甲酸 作用下, 反应 2.0h, 以80%的产率得到4-(1,2-dimethyl-propyl)-morpholine
    参考文献:
    名称:
    Nilsson, Asa; Carlson, Rolf, Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry, 1985, vol. 39, # 3, p. 187 - 190
    摘要:
    DOI:
  • 作为产物:
    描述:
    参考文献:
    名称:
    Reactions of Sulfur- and Phosphorus-Substituted Fluoroalkylating Silicon Reagents with Imines and Enamines under Acidic Conditions
    摘要:
    Nucleophilic fluoroalkylation reactions of imines and enamines with alpha-phenylthio, alpha-phenylsulfonyl, and alpha-diethylphosphoryl substituted fluorinated silanes have been investigated. The reactions are promoted by hydrofluoric acid generated in situ from potassium hydrodifluoride and trifluoroacetic acid. Sulfur reagents worked well with both imines and enamines, whereas phosphorus reagent efficiently coupled only with enamines.
    DOI:
    10.1021/jo202669w
点击查看最新优质反应信息

文献信息

  • Pyridobenzazepine compounds and methods for inhibiting mitotic progression
    申请人:Claiborne F. Christopher
    公开号:US20080045501A1
    公开(公告)日:2008-02-21
    This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.
    这项发明涉及用于治疗癌症的化合物和方法。具体而言,该发明提供了抑制枢纽激酶的化合物,包括这些化合物的药物组合物,以及使用这些化合物治疗癌症的方法。
  • Ring transformation of condensed pyrimidines by enamines and ynamines. Formation of condensed pyridines and condensed diazocines.
    作者:Akira MIYASHITA、Naokata TAIDO、Susumu SATO、Ken-ichi YAMAMOTO、Hitoshi ISHIDA、Takeo HIGASHINO
    DOI:10.1248/cpb.39.282
    日期:——
    A [4+2]-cycloaddition of quinazoline (2) and the 3H-1, 2, 3-triazolo[4, 5-d]pyrimidine 4 with enamines 1a-e resulted in ring transformation into the quinolines, 3a and 3c, and the 3H-1, 2, 3-triazolo[4, 5-b]pyridines, 5a-e, respectively. Similarly, the ynamine 13a cycloadded to 2 and its 4-cyano derivative 6, giving the quinolines, 14a and 14b, respectively.On the other hand, the 3H-1, 2, 3-triazolo[4, 5-d]pyrimidines 4, 15, 8, 16, 17, 18, and 19 underwent [2+2]-cycloaddition with the ynamine 13a, resulting in ring transformation into the corresponding 3H-1, 2, 3-triazolo[4, 5-d]-[1, 3]diazocines 21a-27. The 7-methoxy derivative 20, the 4-methoxy- and 4-cyano-1H-pyrazolo[3, 4-d]pyrimidines, 30 and 31, and the 6-cyano-9H-purine 36 also underwent [2+2]-cycloaddition with 13a to give the corresponding 3H-1, 2-3-triazolo[4, 5-b][1, 5]diazocine 28, 1H-pyrazolo[3, 4-b][1, 5]diazocines, 32 and 33, and 3H-imidazo[4, 5-b]-[1, 5]diazocine 37, respectively.The structures of the 1, 3- and 1, 5-diazocines, 21a and 28, were determined by X-ray crystallography.
    喹唑啉(2)和3H-1, 2, 3-三氮杂[4, 5-d]嘧啶(4)与烯胺(1a-e)进行[4+2]环加成反应,导致环转化为喹啉(3a和3c)和相应的3H-1, 2, 3-三氮杂[4, 5-b]吡啶(5a-e)。类似地,烯氨(13a)与2及其4-氰基衍生物6进行环加成,分别生成喹啉(14a和14b)。另一方面,3H-1, 2, 3-三氮杂[4, 5-d]嘧啶(4、15、8、16、17、18和19)与烯氨(13a)发生[2+2]环加成反应,导致环转化为相应的3H-1, 2, 3-三氮杂[4, 5-d]-[1, 3]二氮环(21a-27)。7-甲氧基衍生物20、4-甲氧基和4-氰基的1H-吡唑[3, 4-d]嘧啶(30和31)以及6-氰基-9H-嘌呤(36)也与13a发生[2+2]环加成,分别生成相应的3H-1, 2-3-三氮杂[4, 5-b][1, 5]二氮环(28)、1H-吡唑[3, 4-b][1, 5]二氮环(32和33)和3H-咪唑[4, 5-b]-[1, 5]二氮环(37)。1, 3-和1, 5-二氮环(21a和28)的结构通过X射线晶体学确定。
  • Phthalazines. XV. Ring transformation of phthalazines into naphthalenes by means of inverse-electron-demand Diels-Alder reaction.
    作者:Etsuo OISHI、Naokata TAIDO、Ken-ichi IWAMOTO、Akira MIYASHITA、Takeo HIGASHINO
    DOI:10.1248/cpb.38.3268
    日期:——
    The 1-substituted phthalazines 6 underwent inverse-electron-demand Diels-Alder reaction with the enamines 3 and ynamines 9, resulting in the formation of 1-substituted naphthalenes.Thus, 1-phthalazinecarbonitrile (6b) reacted with 3a-i to give the corresponding 1-naphthonitriles 7a-e, g, h and 2, 3-kihydro-1-naphthonitriles 8f, i, respectively. Similarly, reaction of 1-(methylsulfonyl)phthalazine (6c) with 3a, b, d, f gave the corresponding 1-(methylsulfonyl)naphthalenes 10a, b, d and 1-(methylsulfonyl)-2, 3-dihydronaphthalene 11f. Furthermore, 1-methylthio- (6e), 1-phenyl- (6f), 1-methyl-(6b), 1-chlorophthalazines (6h) and phthalazine (6a) reacted with 3a to afford the corresponding 4-substituted 2, 3-dihydro-1H-benz[f]indenes 12e-h, a, respectively.A similar ring transformation was found to proceed between 1, 4-phthalazinedicarbonitrile (14) and 1-methyl-1H-indole (13), giving the benzo[b]carbazoledicarbonitrile (15).Compounds 6b and 6c also underwent inverse-electron-demand Diels-Alder reaction with the ynamines 9a, b to give the corresponding 1-cyano-16a, b and 1-(methylsulfonyl)naphthalenes 17a, b, respectively.
    因此,1-酞嗪甲腈(6b)与 3a-i 反应,分别得到相应的 1-萘甲腈 7a-e、g、h 和 2、3-基氢-1-萘甲腈 8f、i。同样,1-(甲磺酰基)酞嗪(6c)与 3a、b、d、f 反应,得到相应的 1-(甲磺酰基)萘 10a、b、d 和 1-(甲磺酰基)-2,3-二氢萘 11f。此外,1-甲硫基(6e)、1-苯基(6f)、1-甲基(6b)、1-氯酞嗪(6h)和酞嗪(6a)与 3a 反应,分别得到相应的 4-取代的 2,3-二氢-1H-苯并[f]茚 12e-h、a。化合物 6b 和 6c 还与亚萘胺 9a 和 b 发生了反电子需求的 Diels-Alder 反应,分别得到了相应的 1-氰基-16a、b 和 1-(甲磺酰基)萘 17a、b。
  • [EN] COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS ET LEURS UTILISATIONS
    申请人:FOGHORN THERAPEUTICS INC
    公开号:WO2022025880A1
    公开(公告)日:2022-02-03
    The present invention relates to methods and compositions for the treatment of BAF-related disorders such as cancers and viral infections.
    本发明涉及用于治疗与BAF相关的疾病,如癌症和病毒感染的方法和组合物。
  • The Use of Trifluoroacetaldehyde Ethyl Hemiacetal or Hydrate in a Simple and Practical Regioselective Synthesis of β-Hydroxy-β-trifluoromethyl Ketones from Enamines and Imines
    作者:Kazumasa Funabiki、Kei Matsunaga、Miwa Nojiri、Wataru Hashimoto、Hitoshi Yamamoto、Katsuyoshi Shibata、Masaki Matsui
    DOI:10.1021/jo026697j
    日期:2003.4.1
    The reaction of trifluoroacetaldehyde ethyl hemiacetal or hydrate with an equimolar amount of enamines, derived from various methyl ketones, smoothly proceeded to give the corresponding beta-hydroxy-beta-trifluoromethyl ketones in high yields. An equimolar amount of imines derived from various methyl ketones with aliphatic, aromatic, and heteroaromatic substituents also readily reacted with trifluoroacetaldehyde
    三氟乙醛乙基半缩醛或水合物与等摩尔量的衍生自各种甲基酮的烯胺的反应平稳进行,以高收率得到相应的β-羟基-β-三氟甲基酮。等摩尔量的衍生自具有脂肪族,芳族和杂芳族取代基的各种甲基酮的亚胺也容易与三氟乙醛乙基半缩醛或水合物反应,以良好或优异的收率得到相应的β-羟基-β-三氟甲基酮。二氟乙醛乙基半缩醛以及五氟丙醛也参与了反应,提供了相应的β-羟基-β-二氟甲基或β-五氟丙基酮的良好产率。
查看更多

同类化合物

(4-甲基环戊-1-烯-1-基)(吗啉-4-基)甲酮 (2-肟基-氰基乙酸乙酯)-N,N-二甲基-吗啉基脲六氟磷酸酯 鲸蜡基乙基吗啉氮鎓乙基硫酸盐 马啉乙磺酸钾 预分散OTOS-80 顺式4-(氮杂环丁烷-3-基)-2,2-二甲基吗啉 顺式-N-亚硝基-2,6-二甲基吗啉 顺式-3,5-二甲基吗啉 顺-2,6-二甲基-4-(4-硝基苯基)吗啉 非屈酯 雷奈佐利二聚体 阿瑞杂质9 阿瑞吡坦磷的二卞酯 阿瑞吡坦杂质 阿瑞吡坦杂质 阿瑞吡坦 阿瑞吡坦 阿瑞匹坦非对映异构体2R3R1R 阿瑞匹坦杂质A异构体 阿瑞匹坦杂质54 阿瑞匹坦-M3代谢物 钾[2 - (吗啉- 4 -基)乙氧基]甲基三氟硼酸 邻苯二甲酸单吗啉 调节安 试剂2-(4-Morpholino)ethyl2-bromoisobutyrate 茂硫磷 苯甲腈,2-(4-吗啉基)-5-[1,4,5,6-四氢-4-(羟甲基)-6-羰基-3-哒嗪基]- 苯甲曲秦 苯甲吗啉酮 苯基2-(2-苯基吗啉-4-基)乙基碳酸酯盐酸盐 苯二甲吗啉一氢酒石酸盐 苯二甲吗啉 苯乙酮 O-(吗啉基羰基甲基)肟 芬美曲秦 芬布酯盐酸盐 芬布酯 脾脏酪氨酸激酶(SYK)抑制剂 脱氯利伐沙班 脱氟雷奈佐利 羟基1-(3-氯苯基)-2-[(1,1-二甲基乙基)氨基]-1-丙酮盐酸盐 福沙匹坦苄酯 福沙匹坦杂质26 福曲他明 碘化N-甲基丙基吗啉 碘化N-甲基,乙基吗啉 硝酸吗啉 盐酸吗啡啉-D8 甲基吗啉-2-羧酸甲酯2,2,2-三氟乙酸盐 甲基N-[3-(乙酰基氨基)-4-[(2-氰基-4,6-二硝基苯基)偶氮]苯基]-N-乙基-&#x3B2-丙氨酸酸酯 甲基4-吗啉二硫代甲酸酯